#USA #Los Angeles #Schall Law Firm #REGENXBIO #RGX-111

Class Action Lawsuit Opportunity for REGENXBIO Investors

The Schall Law Firm, a prominent national legal firm focused on shareholder rights, has issued a reminder to investors regarding a class action lawsuit against REGENXBIO Inc. (NASDAQ: RGNX). This lawsuit centers on serious allegations of securities fraud under the Securities Exchange Act of 1934, specifically violations of §§10(b) and 20(a), along with Rule 10b-5 established by the U.S. Securities and Exchange Commission (SEC).

Timing for Participation

Importantly, the window for investors to join this lawsuit is limited. Those who acquired REGENXBIO's securities during the period from February 9, 2022, to January 27, 2026, are specifically encouraged to reach out to the Schall Law Firm by April 14, 2026. Prospective class members can communicate with the firm directly through their official website or by phone for a free consultation to explore their legal rights and options.

Allegations Against REGENXBIO

At the heart of this lawsuit are claims that REGENXBIO provided investors with false and misleading information regarding their product candidate, RGX-111. Allegations indicate that while the company issued overly positive statements about the product, they were concealing critical negative data regarding its safety and efficacy. Most notably, an incident involving an intraventricular CNS tumor discovered in a trial participant has brought the integrity of the company's public statements into serious question.

These misrepresentations, as outlined in the complaint, led to significant investor losses once the truths surrounding the efficacy and safety of RGX-111 were revealed. As the details unfolded, it became clear that the company's prior communications were materially deceptive during the class period, contributing directly to investors' financial damages.

Next Steps for Investors

Investors who believe they may have suffered losses as a result of these actions are prompted to join the ongoing case to seek compensation. The Schall Law Firm brings extensive experience in securities class action lawsuits and shareholder advocacy, offering representation for affected investors around the globe.

In light of this situation, it is crucial for eligible investors to act swiftly to secure their place in the class. The Schall Law Firm stands ready to assist individuals looking to reclaim their investments lost due to the alleged fraudulent actions of REGENXBIO.

Conclusion

For those who are part of the REGENXBIO community and have endured financial loss due to the company's actions, this is an opportune moment to participate in a collective legal effort. Engaging with a seasoned law firm could not only help you understand your rights but also pave the way to potential recovery of lost funds. Don't hesitate to contact the Schall Law Firm, as the deadline for joining the lawsuit approaches rapidly.